Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Ophthalmic INS-365 to be developed by Inspire in collaboration with Santen

Jan. 5, 1999

AF1 promotes optic nerve regeneration in mouse model of glaucoma

Dec. 17, 1998

Medarex reports setback in phase III trial of MDX-RA

Dec. 15, 1998

FDA advisory committee will meet in January to review KeraVision Ring PMA

Dec. 9, 1998

Senju reports synthesis and evaluation of compounds with multiple pharmacological actions

Dec. 8, 1998

Photogen initiates development of ocular disease Rx; receives U.S. patents for technology

Dec. 7, 1998

Olopatadine combination more effective than loratadine monotherapy in allergic conjunctivitis

Nov. 27, 1998

CytoTherapeutics receives patent protection for ocular delivery of therapeutic substances

Nov. 25, 1998

First marketing approval granted for Vitrase in Mexico; U.S. phase III trials now under way

Nov. 24, 1998

Akorn announces U.S. market introduction for BioLon

Nov. 24, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 14, 2025.
European VCs optimistic for med-tech exit opportunities in 2025
BioWorld MedTech
To say that European investors are optimistic about the outlook for the med-tech sector in 2025 is an understatement. A couple of companies are already listed on...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for February 14, 2025
European VCs bullish on med-tech investments in 2025
BioWorld MedTech
European companies looking for capital should find the fundraising environment more favorable in 2025. Private med-tech financings in January totaled about $2...
Kura/Kyowa Kirin’s ziftomenib hits phase II endpoints in AML
BioWorld
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial...